Type I Interferons Drive the Gastrointestinal Inflammatory Response in a Mouse Model of Parkinson's Disease.

Harrison Waters, Shuyan Chen, Elizabeth Vincan, Dustin J Flanagan, Renate H M Schwab, Peter J Crack, Juliet M Taylor

Abstract read

In one paragraph

Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Harrison WatersDepartment of Biochemistry and Pharmacology, University of Melbourne, Melbourne, Australia.

Shuyan ChenDepartment of Biochemistry and Pharmacology, University of Melbourne, Melbourne, Australia.

Elizabeth VincanDepartment of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia.

Dustin J FlanaganDepartment of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia.

Renate H M SchwabGulbali Institute, Charles Sturt University, Wagga Wagga, Australia.

Peter J CrackDepartment of Biochemistry and Pharmacology, University of Melbourne, Melbourne, Australia.

Juliet M TaylorDepartment of Biochemistry and Pharmacology, University of Melbourne, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by classical motor symptoms due to a loss of dopaminergic neurons in the substantia nigra Methods: Young (10-12 weeks) and aged (40-50 weeks) wild-type and IFN alpha receptor (IFNAR)1 Results: An intrastriatal injection of human α-syn PFFs was shown to initiate a type I IFN-dependent neuroinflammatory response in the gastrointestinal tract of wild-type mice at 6 months postinjection. This response was attributed to an elevation in type I IFN signaling in aged mice that was absent in the IFNAR1 Conclusion: This study has confirmed the type I IFNs modulate the α-syn PFF-induced inflammatory response within the gut, potentiating pathology progression along the gut-brain axis. Early intervention of this type I IFN response may be a potential therapeutic target to limit the progression of PD.

Indexed as

Alpha-SynucleinGut-Brain AxisParkinson’s DiseaseType I Interferons

Identifiers

PMID42022525

DOI10.1016/j.gastha.2026.100929

PMCPMC13098579

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.